Meeting
2017 ASCO Annual Meeting
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950).
Authors
Patrick Schoffski
University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium
Patrick Schoffski , Mark Agulnik , Silvia Stacchiotti , Lara Emily Davis , Victor Manuel Villalobos , Antoine Italiano , Suzanne George , Gregory Michael Cote , Stephen Blakemore , Alicia Clawson , Scott Daigle , Scott Ribich , Maria Roche , Jill Rodstrom , Peter T.C. Ho , Mrinal M. Gounder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02601950
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11057)
DOI
10.1200/JCO.2017.35.15_suppl.11057
Abstract #
11057
Poster Bd #
380
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).
First Author: Mrinal M. Gounder
Poster
2024 ASCO Annual Meeting
TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors.
First Author: Joanna S. Yi
Poster
2020 ASCO Virtual Scientific Program
A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.
First Author: Shiraj Sen
Poster
2016 ASCO Annual Meeting
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.
First Author: Mark Agulnik